Figure 1 plots the number of semaglutide manufacturers requesting NDC codes for semaglutide powder, all organized by the date of the first NDC request
Hepatic or renal impairment these are compounds handled by the liver and kidneys
Health Canada spokesperson Mark Johnson says evaluating generic semaglutide drugs is more complex than many other medication approvals, because the original product was developed using biological processes while generic versions can be made by simpler chemical means
In December 2024, tirzepatide (Zepbound) became the first medication to receive FDA approval specifically for moderate to severe OSA in adults with obesity, based on the SURMOUNT-OSA clinical trials
The synergy it describes is explicitly labeled theoretical
This, in part, reflects the challenge and mistrust of the medical establishment, which worsened during the Covid pandemic, but was already showing strong signs of opposition by the wide adoption of supplements (with a very similar lack of supportive data on efficacy and safety) long before 2020